In addition, with PKCβ as the intervention target, LY333531 inhibited the DCs immune maturation that was induced by diabetic atherosclerosis, reduced the systemic chronic low-grade inflammatory response of diabetes mellitus, and stabilized and reduced the atherosclerotic plaques. This evidence concerns the gene PRKCB and diabetes mellitus.